Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 103

1.

A comparative analysis of clinical and molecular factors with the stage of cervical cancer in a Brazilian cohort.

Amaro-Filho SM, Golub JE, Nuovo GJ, Cunha CB, Levi JE, Villa LL, Andrade CV, Russomano FB, Tristão A, Pires A, Nicol AF.

PLoS One. 2013;8(3):e57810. doi: 10.1371/journal.pone.0057810. Epub 2013 Mar 7.

2.

p16 INK4a and Ki67 expression in normal, dysplastic and neoplastic uterine cervical epithelium and human papillomavirus (HPV) infection.

Calil LN, Edelweiss MI, Meurer L, Igansi CN, Bozzetti MC.

Pathol Res Pract. 2014 Aug;210(8):482-7. doi: 10.1016/j.prp.2014.03.009. Epub 2014 Apr 4.

PMID:
24793773
3.
4.

[Association of p16, p53, Ki-67 expressions with high-risk human papilloma virus infection in cervical intraepithelial neoplasia].

Shi J, Zheng JS, Yin F, Hu WW, Huang XJ, Zhou XL.

Nan Fang Yi Ke Da Xue Xue Bao. 2007 Apr;27(4):515-7. Chinese.

5.
6.

Ki-67, cyclin E, and p16INK4 are complimentary surrogate biomarkers for human papilloma virus-related cervical neoplasia.

Keating JT, Cviko A, Riethdorf S, Riethdorf L, Quade BJ, Sun D, Duensing S, Sheets EE, Munger K, Crum CP.

Am J Surg Pathol. 2001 Jul;25(7):884-91.

PMID:
11420459
7.

Immunohistochemical expression of cyclin D1, p16Ink4a, p21WAF1, and Ki-67 correlates with the severity of cervical neoplasia.

Portari EA, Russomano FB, de Camargo MJ, Machado Gayer CR, da Rocha Guillobel HC, Santos-Rebouças CB, Brito Macedo JM.

Int J Gynecol Pathol. 2013 Sep;32(5):501-8. doi: 10.1097/PGP.0b013e31826f5cf6.

PMID:
23896712
8.

Expression of cyclin-dependent kinase inhibitors p16MTS1, p21WAF1, and p27KIP1 in HPV-positive and HPV-negative cervical adenocarcinomas.

Milde-Langosch K, Riethdorf S, Kraus-Pöppinghaus A, Riethdorf L, Löning T.

Virchows Arch. 2001 Jul;439(1):55-61.

PMID:
11499840
9.

High-risk human papillomavirus E7 oncoprotein detection in cervical squamous cell carcinoma.

Ressler S, Scheiden R, Dreier K, Laich A, Müller-Holzner E, Pircher H, Morandell D, Stein I, Viertler HP, Santer FR, Widschwendter A, Even J, Jansen-Dürr P, Capesius C, Zwerschke W.

Clin Cancer Res. 2007 Dec 1;13(23):7067-72.

10.

Expression of p16/Ki-67 in ASC-US/LSIL or Normal Cytology with Presence of Oncogenic HPV DNA.

Solares C, Velasco J, Álvarez-Ruiz E, González-Fernández L, Encinas AI, Astudillo A, Schneider J.

Anticancer Res. 2015 Nov;35(11):6291-5.

PMID:
26504065
11.

The expression of p16 (INK4a) and Ki-67 in relation to high-risk human papilloma viral load and residual disease after conization with positive margins.

Song SH, Park HM, Eom DW, Lee JK, Lee NW, Kim AR, Hur JY, Lee KW, Park YK, Saw HS.

Int J Gynecol Cancer. 2007 Jul-Aug;17(4):858-67. Epub 2007 Mar 15.

PMID:
17367326
12.

p16/Ki-67 dual staining in cervico-vaginal cytology: correlation with histology, Human Papillomavirus detection and genotyping in women undergoing colposcopy.

Donà MG, Vocaturo A, Giuliani M, Ronchetti L, Rollo F, Pescarmona E, Carosi M, Vocaturo G, Benevolo M.

Gynecol Oncol. 2012 Aug;126(2):198-202. doi: 10.1016/j.ygyno.2012.05.004. Epub 2012 May 12.

PMID:
22588180
13.

Correlation of MCM2 detection with stage and virology of cervical cancer.

Amaro Filho SM, Nuovo GJ, Cunha CB, Ramos Pereira Lde O, Oliveira-Silva M, Russomano F, Pires A, Nicol AF.

Int J Biol Markers. 2014 Dec 9;29(4):e363-71. doi: 10.5301/jbm.5000081.

PMID:
24706378
14.

Up-regulation of expression and lack of 5' CpG island hypermethylation of p16 INK4a in HPV-positive cervical carcinomas.

Ivanova TA, Golovina DA, Zavalishina LE, Volgareva GM, Katargin AN, Andreeva YY, Frank GA, Kisseljov FL, Kisseljova NP.

BMC Cancer. 2007 Mar 14;7:47.

15.
16.

P16 overexpression and human papillomavirus infection in small cell carcinoma of the uterine cervix.

Masumoto N, Fujii T, Ishikawa M, Saito M, Iwata T, Fukuchi T, Susumu N, Mukai M, Kubushiro K, Tsukazaki K, Nozawa S.

Hum Pathol. 2003 Aug;34(8):778-83.

PMID:
14506638
17.

Performance of p16/Ki-67 immunostaining to detect cervical cancer precursors in a colposcopy referral population.

Wentzensen N, Schwartz L, Zuna RE, Smith K, Mathews C, Gold MA, Allen RA, Zhang R, Dunn ST, Walker JL, Schiffman M.

Clin Cancer Res. 2012 Aug 1;18(15):4154-62. doi: 10.1158/1078-0432.CCR-12-0270. Epub 2012 Jun 6.

18.

Correlation between p14(ARF)/p16(INK4A) expression and HPV infection in uterine cervical cancer.

Kanao H, Enomoto T, Ueda Y, Fujita M, Nakashima R, Ueno Y, Miyatake T, Yoshizaki T, Buzard GS, Kimura T, Yoshino K, Murata Y.

Cancer Lett. 2004 Sep 15;213(1):31-7.

PMID:
15312681
19.

The role of cyclins and cyclins inhibitors in the multistep process of HPV-associated cervical carcinoma.

Bahnassy AA, Zekri AR, Alam El-Din HM, Aboubakr AA, Kamel K, El-Sabah MT, Mokhtar NM.

J Egypt Natl Canc Inst. 2006 Dec;18(4):292-302.

20.

Human papillomavirus prevalence and type distribution in invasive cervical cancer in sub-Saharan Africa.

Denny L, Adewole I, Anorlu R, Dreyer G, Moodley M, Smith T, Snyman L, Wiredu E, Molijn A, Quint W, Ramakrishnan G, Schmidt J.

Int J Cancer. 2014 Mar 15;134(6):1389-98. doi: 10.1002/ijc.28425. Epub 2013 Nov 14.

Supplemental Content

Support Center